Moderna (MRNA) said late Friday it has been awarded $590 million by the US Department of Health and Human Services for the development of mRNA-based influenza vaccines.
The project will back the late-stage development and licensure of pre-pandemic mRNA-based vaccines and support the expansion of trials for up to five additional subtypes of pandemic influenza, the company said.
Moderna said that it launched a phase 1/2 trial in 2023 to get safety and immunogenicity data of a candidate pandemic influenza vaccine, mRNA-1018, in adults. The trial included vaccine candidates against the H5 and H7 bird flu viruses.
Based on positive preliminary results from the phase 1/2 trial, the company said it is preparing to move mRNA-1018 into phase 3.
Moderna shares were rising 3.7% in after-hours activity.
Price: 35.31, Change: +1.25, Percent Change: +3.67
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.